(Q37378350)

English

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

scientific article published on September 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

0 references

0 references

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michelle A. Petri

7

object named as

Michelle A Petri

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

6

object named as

Joan T Merrill

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Ellen M Ginzler

8

object named as

Ellen M Ginzler

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Daniel J Wallace

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

William Stohl

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Richard A Furie

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Jeffrey R Lisse

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

James D McKay

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

W Winn Chatham

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

W Joseph McCune

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Vivian Fernandez

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Marc R Chevrier

12

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Z John Zhong

13

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

William W Freimuth

14

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

61

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1168-1178

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Challenges in bringing the bench to bedside in drug development for SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BCMA is essential for the survival of long-lived bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

14 September 2017

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

28 September 2017

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

26 June 2018

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

A trial of contraceptive methods in women with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Classification and definition of major flares in SLE clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition and treatment of lupus flares measured by the BILAG index

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.24699

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37378350&oldid=2226267039"